Simon Plyte
Chief Scientific Officer BIOMUNEX Pharmaceuticals
Dr Simon Plyte has over 25 years’ experience in the pharmaceutical industry working in both big Pharma and small Biotech. He has predominantly been involved in the preclinical development of novel drugs (up to First in human studies) for the treatment of cancer (biologics and chemical entities) and the last 10 years have been focussed on Muli-specific antibodies in immune oncology. He is currently the Chief Scientific Officer at Biomunex Pharmaceuticals in Paris, where his team are predominantly focussed on developing MAIT engagers, a first-in-class innovative approach for the treatment of cancer.
Seminars
Wednesday 10th December 2025
MAIT Engagers: Bypassing Treg Suppression & CRS in Solid Tumours
1:30 pm
- Exploring how MAIT Engagers selectively activate cytotoxic T cells without engaging CD4⁺ regulatory T cells, preventing tumour-localised immune dampening
- Preventing CRS without CD4 binding – discussing how MAIT Engagers are designed to prevent systemic immune overstimulation by avoiding broad T cell activation
- Redefining T cell redirection – as a next-gen alternative to CD3-based approaches, seeing how MAIT Engagers offer a strategic leap in precision, potency, and safety in immune-oncology
